Developing an Artificial Pancreas The History & Future of Dose Safety

Similar documents
Diabetes through my eyes. Rick Mauseth, M.D. W.A.D.E. April 2013

JDRF Perspective on Closed Loop

Florida Network Symposium

Future Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida

Proposed Clinical Application for Tuning Fuzzy Logic Controller of Artificial Pancreas utilizing a Personalization Factor

What is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming

The Quest for the Artificial Pancreas Clinical and Engineering Studies

Emerging Automated Insulin Delivery Systems

LOCATIONS ( GET SUPPORT ( /GET-SUPPORT/) DONATE (

UvA-DARE (Digital Academic Repository) The artificial pancreas Kropff, J. Link to publication

In Silico Preclinical Trials: Methodology and Engineering Guide to Closed-Loop Control in Type 1 Diabetes Mellitus

Hope for an ARTIFICIAL PANCREAS

CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION

More Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center

Advances in Managing Diabetes in Youth. March 1, 2012

The Role of Process Systems Engineering in the Quest for the Artificial Pancreas

IJESRT INTERNATIONAL JOURNAL OF ENGINEERING SCIENCES & RESEARCH TECHNOLOGY PID CONTROLLER FOR BLOOD GLUCOSE CONTROL Ajmal M M *, C R Srinivasan *

Inpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm

ARTIFICIAL ENDOCRINE PANCREAS: FROM BENCH TO BEDSIDE

SIMULATIONS OF A MODEL-BASED FUZZY CONTROL SYSTEM FOR GLYCEMIC CONTROL IN DIABETES

Artificial Pancreas Technologies: New Tools to Improve Diabetes Care Today and Tomorrow

JDRF RESEARCH UPDATE. Daniel Finan, Ph.D. Research Director

CGM and Closing The Loop

DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson

Reduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home

Hypoglycemia Detection and Prediction Using Continuous Glucose Monitoring A Study on Hypoglycemic Clamp Data

Fayrouz Allam Tabbin Institute for Metallurgical Studies, Helwan, Egypt

Artificial Pancreas Device System (APDS)

The Artificial Pancreas

Technology in Diabetes Management Irl B. Hirsch, MD University of Washington

INTERNATIONAL JOURNAL OF PURE AND APPLIED RESEARCH IN ENGINEERING AND TECHNOLOGY

Non Linear Control of Glycaemia in Type 1 Diabetic Patients

Faculty Disclosure. No, nothing to disclose Yes, please specify: Medtronic Johnson & Johnson. Ownership/ Equity Position.

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

The next five years in diabetes technology: closed-loop systems

Institutional Investor & Analyst Day. September 25, 2018

Active Insulin Infusion Using Fuzzy-Based Closed-loop Control

OBJECTIVES THE PAST INNOVATIVE TECHNOLOGY & DIABETES DIABETES MIS MANAGEMENT IMPROVEMENTS IN DIABETES MANAGEMENT

When Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida

The Realities of Technology in Type 1 Diabetes

The Plan for a World without T1D

DESIGN AND CONTROL OF THE ARTIFICAL PANCREAS

NEWS BRIEFING Advances in Technology. moderated by: Irl Hirsch, MD University of Washington Medical Center

Toward Plug and Play Medical Cyber-Physical Systems (Part 2)

Insulin Administration for People with Type 1 diabetes

Multivariate Statistical Analysis to Detect Insulin Infusion Set Failure

THE MINIMED 670G SYSTEM SCHOOL NURSE GUIDE

VIRTUAL PATIENTS DERIVED FROM THE

Understanding the CareLinkTM Sensor Meter Overview Report: Page 1

PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)

Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?

A Closed-Loop Artificial Pancreas Using Model Predictive Control and a Sliding Meal Size Estimator. Abstract. Introduction

Who has responsibility for emerging technologies in diabetes management

C o n n e c t e d I n s u l i n D e l i v e r y S y s t e m

DIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT

The artificial pancreas: the next step in connectivity and digital treatment of type 1 diabetes

DIAGNOSIS OF DIABETES NOW WHAT?

Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD

Diabetes Management: Current High Tech Innovations

1. Continuous Glucose Monitoring

ACCELERATING PROGRESS. Aaron J. Kowalski Ph.D. JDRF Chief Mission Officer

Diabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018

Federal Initiatives in Smart Communities and the Internet of Things

An event-based point of view on the control of insulin-dependent diabetes

NEW GENERATION CLOSED LOOP INSULIN DELIVERY SYSTEM

[Frida Svendsen and Jennifer Southern] University of Oxford

Artificial Pancreas Goes Outpatient: A New Diabetes Ecosystem

Glucose Concentration Simulation for Closed-Loop Treatment in Type 1 Diabetes

Subject Index. Breastfeeding, self-monitoring of blood glucose 56

Leading Endocrinologists, Researchers Herald Current Regimens And New Technologies in Path to Artificial Pancreas

The development of an artificial

FDA/JDRF/NIH Workshop on Innovation Towards an Artificial Pancreas. April 9-10, 2013; Bethesda, MD Day #1 Highlights

Automated control of an adaptive bi-hormonal, dual-sensor artificial pancreas and evaluation during inpatient studies

QUESTION 4. WHAT CLINICAL DATA ARE CURRENTLY AVAILABLE TO SUPPORT EXPANDED CGM COVERAGE BY PAYERS AS PERTAINS TO QUESTIONS 1 AND 3?

Insulin Control System for Diabetic Patients by Using Adaptive Controller

Ambulatory Artificial Pancreas Platform (AAPP) User Manual

Mean Glucose Slope Principal Component Analysis Classification to Detect Insulin Infusion Set Failure

UNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE

Insulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)

Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring

Understanding the CareLink TM Therapy Management Dashboard Report

The Special Diabetes Program

Advances Towards the Bionic Pancreas.

Type 1 diabetes (T1D) is one of the most common chronic

Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico

ADA 2018 JUN 25, 2018 ORLANDO, FLORIDA

From In- to Out-patient Artificial Pancreas Studies: Results And New Developments

Analyzing Glucose Data

Diabetes Care 33: , 2010

7/18/2017. Everything discussed in this presentation is off-label. (And that s ok.) Dana Lewis Founder, #OpenAPS WARNING: Disclosure to Participants

GLYCEMIC CONTROL SURVEY

ADVANCES in NATURAL and APPLIED SCIENCES

Outline. Model Development GLUCOSIM. Conventional Feedback and Model-Based Control of Blood Glucose Level in Type-I Diabetes Mellitus

10:20 AM March 5, B 100% 235 u. 124 mg/dl 3 HRS INSULIN ON BOARD:

Impact of sensing and infusion site dependent dynamics on insulin bolus based meal compensation

Monitoring of Blood Glucose Level

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Do women have to come off DAFNE when pregnant?

Transcription:

Developing an Artificial Pancreas The History & Future of Dose Safety Richard Mauseth, MD!! IMPROVING!!! LIVES.!CURING!!TYPE!1 DIABETES.

Controller Methods 1. Proportional-Integral-Derivative (PID) 2. Model Predictive Control (MPC) 3. Fuzzy Logic (FL)

People with diabetes respond very differently to the same conditions BG (mg/dl) 400 350 300 250 200 150 Exercise Trials Subj1 Subj2 Subj3 Subj4 Subj5 Subj6 Subj7 100 50 0 14:00 16:00 18:00 20:00 22:00 0:00 2:00 4:00 6:00 8:00 10:00 Time

The Fuzzy Logic Process Physicians Knowledge

Different Paths / Different Doses 300 Rising Blood Glucose 300 Falling Blood Glucose 250 250 200 200 150 150 100 Decreasing 100 Decreasing 50 Flat Increasing 50 Flat Increasing 0 11:00 AM 12:00 PM 1:00 PM 2:00 PM 3:00 PM 0 11:00 AM 12:00 PM 1:00 PM 2:00 PM 3:00 PM

Fuzzy Logic Dosing Matrix

The Fuzzy Logic Process in Detail

2002-2003 Boeing technology meeting Fuzzy logic versus others Evergreen Hospital IRB Q 15 minute venous glucoses Entered into computer given dose which was entered 2005 Continuous glucose sensing 2005 APS consortium

Data from 2003-2004 Studies Version 0.9 controller

2008 Aaron Kowalski at JDRF DTM poster Frank Doyle as UCSB In silico testing Ardy Johnson at JDRF

Differing response based on Personalization Factor (PF)

Differing response based on Personalization Factor (PF)

2010 Innovative Grant JDRF funded in bad economic time BRI IRB and FDA IDE approval Four part study Correction of blood sugar, purposely elevated post dinner Blood glucose overnight Blood glucose small and large meals Ten subjects- 24 hours Version 1.5 of controller

Innovative Grant Results 350" 300" "Sensor"BG"Avg" "YSI"BG"Avg" 250" BG#(mg/dL)# 200" 150" 100" 50" Version 1.5 controller 0" 20:00" 22:00" 0:00" 2:00" 4:00" 6:00" 8:00" 10:00" 12:00" 14:00" 16:00" 18:00" 20:00"

Timeline for FDA Funded Study 0 months - idea 4-6 months - write a grant, get institutional approvals for both academics and budget and submit 6-9 months - review a grant 10-12 months - to accept grant 12-15 months - FDA and IRB approval 15-24 months - to do study 24 months - review results 30 months - published results

2012 NIH - JDRF Software development- NIH Stress testing- JDRF

2012-13 Exercise Protocol

Exercise Study Results Version 2.0, 2.1 controller

2012-13 Pizza Protocol

Pizza Study Results Version 2.0, 2.1 controller

2011-2014 NIH Studies Software development Meal detection Sensor noise reduction Blood sugar prediction Remote monitoring Clinical- ad lib living in CRC 40 eight hour studies to compare day to day Version 2.2 of controller

2014 Future Guarded outpatient studies 30 subjects Randomized crossover 68 hours in facility, able to cook, exercise, order take out food, as they would at home Remotely monitored for safety Compare self control versus controller control Version 3.0 of controller

2014 Future - Medtronic AAGC System

2015 Future Outpatient clinical trials New sensors Integration of pump and sensor Remote monitoring of patients Automated warnings Faster insulin Learning Version 4.0 of controller

Our Team

JDRF AP Consortium Sites 18 sites worldwide running clinical trials, providing engineering resources, or doing both: Benaroya Oregon Stanford W. Ontario I.I.T. Rensselaer Montreal Harvard Cambridge Perth Melbourne UCSB/ Sansum Colorado Virginia Yale Montpellier Pavia/Padova Israel Jaeb Center for Health Research, Tampa, FL ConsorJum CoordinaJng Center

Backup Slides

Controller Technology CGM AP Controller Insulin The majority of AP controller teams utilize Proportional Integral Derivative (PID) or Model Predictive Control (MPC) technologies Other teams utilize fuzzy logic (FL) To calculate insulin doses, PID and MPC controllers employ a mathematical model of the system to be controlled, human glucoregulatory system. The models are based on a set of equations. The effectiveness of the dosing is dependent on the fidelity of the model. FL controllers calculate insulin doses based solely on how a clinical expert would interpret the CGM inputs. FL controllers make no assumptions about the system being controlled. The effectiveness of the dosing is dependent on the expertise of the clinicians and how that was codified.